Evidence SummariesEvidence Summary

Febrile Neutropenia in ED

Evidence-summary style response with triage, workup, empiric antibiotics, and disposition logic.

Query: What's the ED management of febrile neutropenia?

Summary

In the ED, febrile neutropenia is managed as a potential medical emergency. The initial approach emphasizes rapid assessment, early aggressive resuscitation in unstable patients, timely acquisition of appropriate laboratories (including blood cultures from all central line lumens and, when indicated, peripheral cultures and evaluation for other infection sources), and prompt administration of broad-spectrum empiric antibiotics (typically an anti‐pseudomonal beta-lactam, with additional agents if the patient is unstable or if resistant organisms are suspected). Risk stratification—often performed in conjunction with oncology—is essential to determine whether a patient may be safely managed as an outpatient or requires inpatient care.

At-a-glance

StepKey Actions
Early Recognition & Triage- Identify febrile neutropenic patients (temp >38.3°C/or >38°C sustained, with ANC <500 cells/µL for severe cases).
- Recognize that these patients may present with subtle signs despite significant immunosuppression 14.
Resuscitation- For hemodynamic instability: begin IV/IO fluid boluses immediately and consider early pressors if indicated.
- Rapid resuscitation is critical, as presentation may be deceptively benign 14.
Laboratory Workup- CBC with differential to confirm neutropenia.
- Blood cultures from all central line lumens; consider an additional peripheral culture to increase diagnostic yield, balancing the risk of contamination and pain 1.
- Other cultures (urinalysis, urine culture, site-specific cultures) and additional labs like BMP.
- Chest X-ray if pulmonary signs/symptoms are present 14.
Empiric Antibiotics- Initiate empiric broad-spectrum antibiotics promptly (goal within 60 minutes to 2 hours of ED arrival):
  • Anti-pseudomonal beta-lactam (e.g., cefepime, carbapenem, or piperacillin-tazobactam) is standard.
  • Consider adding a second agent (aminoglycoside or glycopeptide) if the patient is unstable or if there is suspicion for resistant infections 14.
Risk Stratification & Disposition- Assess risk factors (e.g., recent chemotherapy, prior febrile neutropenia events, mucositis, central line presence) to determine high vs low risk.
- Collaborate with the patient’s oncology team.
- Low-risk patients may be eligible for outpatient management with oral antibiotics and close follow-up; those at high risk should be admitted for continued IV antibiotic therapy and monitoring 12.

References